+33 (0)1 41 19 21 99 | Tous les sites

TSI.com (0)

Life Sciences

|

Logiciel

Service

Contact

TSI.com
(0)

Menu

Abbreviated Impactor Measurement (AIM) Equipment

The Abbreviated Impactor Measurement (AIM) method provides a more efficient alternative to full-resolution cascade impactor testing for aerodynamic particle size distribution (APSD). AIM offers a quicker process for assessing drug particle size, which is especially useful in early-stage development, helping device manufacturers and drug companies shorten development timelines.
 

Originally used for rough particle size estimates, AIM has evolved to be included in FDA submissions and ongoing quality control testing. It allows for effective mass balance exercises while reducing the time and effort required for analysis.
 

Abbreviated impactors such as the Fast Screening Impactor (FSI), Fast Screening Andersen (FSA), and Reduced Next Generation Impactor (rNGI) are popular tools that deliver results transferable to full-resolution devices, like the Andersen Impactor, making AIM an essential tool for streamlined inhalation product development and testing.

Produits

Fast Screening Andersen (FSA)

*Merci de noter que cette page est disponible en anglais uniquement.*

Voir le produit

Fast Screening Impactor (FSI)

*Merci de noter que cette page est disponible en anglais uniquement.*

Voir le produit

Abbreviated impactor measurement (AIM) is a proven approach for reducing test time during inhalation product development and routine checks. Instead of measuring drug mass on every impactor stage, AIM focuses on a reduced set of critical stages or impactor groupings to help you reach early conclusions faster. The result is faster cycle times for formulation screening, device tuning, and stability trending — without fully committing resources to a full cascade impaction run when it is not required.

What AIM Helps You Do

  • Accelerate screening: Support rapid go/no-go decisions during early development and method refinement.
  • Improve resource allocation: Reserve full NGI testing for confirmatory studies while using AIM for high-frequency checks.
  • Support consistency: Maintain standardized workflows with dedicated fixtures, controlled actuation, and compatible software.
  • Bridge to full impaction: Correlate AIM outputs to traditional NGI results to help inform study design.

Typical Applications

  • Pre-formulation and excipient selection
  • Early device characterization, including actuator and orifice changes
  • Stability trending where full stage resolution is not needed
  • Process monitoring and in-process control checks

Key Features

  • Modular hardware that integrates with existing NGI setups
  • Data analysis tools that calculate relevant APSD metrics and trending KPIs
  • Compatible sample preparation for efficient extraction and quantitation
  • Software options that support data integrity practices and method templates

Standards Awareness

AIM workflows are widely used as a complementary method alongside pharmacopeial guidance for APSD (for example, USP <601> and Ph. Eur. 2.9.18). AIM does not replace compendial testing; it supports faster decision-making in development and process environments. Documentation templates, method parameters, and controlled actuation profiles help support consistent execution and robust records.

By combining AIM with automated actuation, controlled flow, and data analysis software, laboratories can streamline decision points across development milestones. The outcome is a more agile program, with better use of personnel and equipment and a stronger foundation for subsequent full NGI testing.


   close carousel